GHRS
GH Research PLC
NASDAQ · Healthcare · Biotechnology · IE
$28.23
+1.11%Aug 6, 2026, 11:00 UTC
GH Research PLC completed GH001-HV-106, a Phase 1 clinical pharmacology trial of its proprietary aerosol delivery device in healthy volunteers, and GH001-HV-109, an IND-opening Phase 1 trial of GH001 in healthy volunteers in the United States.
Source:Aug 6, 2026, 11:00 UTC
GH Research PLC reported financial results for the quarter ended June 30, 2026, with cash, cash equivalents and marketable securities of $362.7 million as of that date.
Source: